Gossamer Bio, Inc.
9.605USD
+0.1450 (+1.53%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on GOSS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$3.93▲ | -$6.55 | 0 | 0 |
| Next quarter | -$4.93▲ | -$5.14 | 1 | 0 |
| Current year | -$18.01▲ | -$34.08 | 1 | 0 |
| Next year | -$15.61▼ | -$7.73 | 1 | 0 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$9.99 | -$8.17 | +1.82 (+18.2%) |
| 2026-03-31 | -$13.64 | -$16 | -2.36 (-17.3%) |
| 2025-12-31 | -$15.65 | -$16.8 | -1.15 (-7.3%) |
| 2025-09-30 | -$15.77 | -$16.8 | -1.03 (-6.5%) |
89 ratings from 19 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Chardan Capital | Maintained | Buy | $160 | Oct 15, 2026 |
| Chardan Capital | Initiated | Buy | $160 | Oct 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $2 $90 | Sep 21, 2026 |
| Piper Sandler | Maintained | Overweight | $15 $4 | Aug 14, 2026 |
| Leerink Partners | Upgraded from Market Perform | Outperform | $1 | Jul 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $2 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $5 $2 | Jun 25, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $5 | May 26, 2026 |
| Barclays | Maintained | Underweight | $0.3 $0.28 | May 19, 2026 |
| Cantor Fitzgerald | Downgraded from Overweight | Neutral | — | Mar 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10 $5 | Mar 6, 2026 |
| Oppenheimer | Maintained | Outperform | $12 $3 | Mar 5, 2026 |
| Wedbush | Downgraded from Outperform | Neutral | $6 $1 | Feb 24, 2026 |
| Barclays | Downgraded from Overweight | Underweight | $9 $0.3 | Feb 24, 2026 |
| Leerink Partners | Downgraded from Outperform | Market Perform | $6 $1 | Feb 24, 2026 |
| Barclays | Initiated | Overweight | $9 | Jan 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $10 | Jan 22, 2026 |
| Cantor Fitzgerald | Reiterated | Overweight | — | Sep 11, 2025 |
| UBS | Upgraded from Neutral | Buy | $1.25 $9 | Sep 10, 2025 |
| Wedbush | Maintained | Outperform | $4 $5 | Aug 6, 2025 |
| Scotiabank | Initiated | Sector Outperform | $11 | Jul 14, 2025 |
| Goldman Sachs | Maintained | Buy | $7 $8 | May 16, 2025 |
| Wedbush | Reiterated | Outperform | $4 | May 16, 2025 |
| Goldman Sachs | Maintained | Buy | $8 $7 | Apr 17, 2025 |
| Wedbush | Reiterated | Outperform | $4 | Mar 14, 2025 |
20 filings from 14 insiders · 63 buy / 34 sell over 6m
Officers and directors of GOSS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Milligan SandraDirector | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| Daniel Thomas ODirector | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| Ciongoli Gregory AustinDirector | GrantStock Option (Right to Buy) | 30.0k | — | — | Sep 23, 2026 |
| Drynan SkyeDirector | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| Quisel John DDirector | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| Cox Russell J.Director | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| Nathan Steven DDirector | GrantStock Option (Right to Buy) | 10.0k | — | — | Sep 23, 2026 |
| SMITH ROBERT PAUL JROfficer | Grant | 93.8k | — | — | Jan 2, 2026 |
| CHRISTIAN WAAGEOfficer | Grant | 84.5k | — | — | Jan 2, 2026 |
| ARANDA RICHARDOfficer | Grant | 93.8k | — | — | Jan 2, 2026 |
| PETERSON CARYNOfficer | Grant | 84.5k | — | — | Jan 2, 2026 |
| GIRAUDO BRYAN M.Chief Operating Officer | Grant | 115.8k | — | — | Jan 2, 2026 |
| HASNAIN FAHEEMChief Executive Officer | Grant | 280.0k | — | — | Jan 2, 2026 |
| SMITH ROBERT PAUL JROfficer | Grant | 162.5k | — | — | Oct 1, 2025 |
| CHRISTIAN WAAGEOfficer | Grant | 125.0k | — | — | Oct 1, 2025 |
| ARANDA RICHARDOfficer | Grant | 162.5k | — | — | Oct 1, 2025 |
| PETERSON CARYNOfficer | Grant | 125.0k | — | — | Oct 1, 2025 |
| GIRAUDO BRYAN M.Chief Operating Officer | Grant | 181.3k | — | — | Oct 1, 2025 |
| HASNAIN FAHEEMChief Executive Officer | Grant | 437.5k | — | — | Oct 1, 2025 |
| MILLIGAN SANDRADirector | Buy | 26.1k | $1.92 | $50k | Aug 19, 2025 |
No analyst notes on GOSS yet.
Members whose judged calls on GOSS have played out most reliably.
No settled calls on GOSS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
6 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 3 | 3 | 0 | 1 | Hold2.63 |
| 1 mo ago | 1 | 2 | 3 | 0 | 1 | Hold2.71 |
| 2 mo ago | 1 | 2 | 3 | 0 | 1 | Hold2.71 |
| 3 mo ago | 1 | 2 | 3 | 0 | 1 | Hold2.71 |